Treatment of in-transit melanoma with intralesional Bacillus Calmette-Guérin (BCG) and topical imiquimod 5% cream: A report of 3 cases

Nour Kibbi, Stephan Ariyan, Mark Faries, Jennifer N. Choi*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

Local therapy for in-transit melanoma (ITM) is a treatment alternative for patients who are not good candidates for systemic therapy, regional therapy, or surgical management. In this case report, we describe 3 patients with ITM who were treated with intralesional Bacillus Calmette-Guérin (ILBCG) and/or topical imiquimod. Treatment course was dictated by the clinical response. Patient 1's response to ILBCG monotherapy was not sufficient to cause disease regression; however, transition to topical imiquimod therapy resulted in complete and sustained response. Although patient 2 responded to ILBCG and imiquimod, she developed a hypersensitivity reaction to ILBCG; when topical imiquimod was continued as monotherapy, her clinical response was complete. Patient 3 responded completely to ILBCG monotherapy in injected lesions, but expired shortly thereafter from unrelated disease. Reports like this one are needed to define the success measures of local therapy in the treatment of ITM.

Original languageEnglish (US)
Pages (from-to)371-375
Number of pages5
JournalJournal of Immunotherapy
Volume38
Issue number9
DOIs
StatePublished - Oct 9 2015

Keywords

  • ILBCG
  • In-transit melanoma
  • Intralesional Bacillus Calmette-Guérin
  • Local therapy
  • Topical imiquimod

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of in-transit melanoma with intralesional Bacillus Calmette-Guérin (BCG) and topical imiquimod 5% cream: A report of 3 cases'. Together they form a unique fingerprint.

Cite this